12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NanoString Breast Cancer Intrinsic Subtyping Assay update

NanoString began a second validation study to evaluate its NanoString Breast Cancer Intrinsic Subtyping Assay on samples from more than 1,000 postmenopausal female patients with hormone receptor-positive,...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >